HemoShear completes initial development phase of new cancer drug discovery platform
Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
Join Bürkert industry experts and Business Review Webinars, on 25 November to learn more about valuable insights to help your business. The first of a series of webinars
Striverdi Respimat has been prescribed as a once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema The